{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:38:22Z","timestamp":1764175102205,"version":"3.41.2"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013297","name":"Eurostars","doi-asserted-by":"publisher","award":["E!12151"],"award-info":[{"award-number":["E!12151"]}],"id":[{"id":"10.13039\/100013297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Persistent human papillomavirus (HPV) infections are causative for cervical neoplasia and carcinomas. Despite the availability of prophylactic vaccines, morbidity and mortality induced by HPV are still too high. Thus, an efficient therapy, such as a therapeutic vaccine, is urgently required. Herein, we describe the development and validation of <jats:italic>Macaca fascicularis<\/jats:italic> papillomavirus type 3 (MfPV3) antigens delivered <jats:italic>via<\/jats:italic> nucleic-acid and adenoviral vectors in outbred mouse models. Ten artificially fused polypeptides comprising early viral regulatory proteins were designed and optionally linked to the T cell adjuvant MHC-II-associated invariant chain. Transfected HEK293 cells and A549 cells transduced with recombinant adenoviruses expressing the same panel of artificial antigens proved proper and comparable expression, respectively. Immunization of outbred CD1 and OF1 mice led to CD8<jats:sup>+<\/jats:sup> and CD4<jats:sup>+<\/jats:sup> T cell responses against MfPV3 antigens after DNA- and adenoviral vector delivery. Moreover, <jats:italic>in vivo<\/jats:italic> cytotoxicity of vaccine-induced CD8<jats:sup>+<\/jats:sup> T cells was demonstrated in BALB\/c mice by quantifying specific killing of transferred peptide-pulsed syngeneic target cells. The use of the invariant chain as T cell adjuvant enhanced the T cell responses regarding cytotoxicity and <jats:italic>in vitro<\/jats:italic> analysis suggested an accelerated turnover of the antigens as causative. Notably, the fusion-polypeptide elicited the same level of T-cell responses as administration of the antigens individually, suggesting no loss of immunogenicity by fusing multiple proteins in one vaccine construct. These data support further development of the vaccine candidates in a follow up efficacy study in persistently infected <jats:italic>Macaca fascicularis<\/jats:italic> monkeys to assess their potential to eliminate pre-malignant papillomavirus infections, eventually instructing the design of an analogous therapeutic HPV vaccine.<\/jats:p>","DOI":"10.3389\/fimmu.2021.761214","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:26:56Z","timestamp":1635406016000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs"],"prefix":"10.3389","volume":"12","author":[{"given":"Patrick","family":"Neckermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ditte Rahbaek","family":"Boilesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Willert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cordula","family":"Pertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Schr\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Asbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Johannes","family":"Holst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-8-20","article-title":"Prevalence and Type Distribution of High-Risk Human Papillomavirus in Patients With Cervical Cancer: A Population-Based Study","volume":"8","author":"Haghshenas","year":"2013","journal-title":"Infect Agent Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13669-016-0165-z","article-title":"Primary Prevention of HPV Through Vaccination: Update on the Current Global Status","volume":"5","author":"Brotherton","year":"2016","journal-title":"Curr Obstet Gynecol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall Efficacy of HPV-16\/18 AS04-Adjuvanted Vaccine Against Grade 3 or Greater Cervical Intraepithelial Neoplasia: 4-Year End-Of-Study Analysis of the Randomised, Double-Blind PATRICIA Trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of Human Papillomavirus 16\/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.4.421","article-title":"Therapeutic Human Papillomavirus Vaccines: Current Clinical Trials and Future Directions","volume":"8","author":"Hung","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural History of Cervicovaginal Papillomavirus Infection in Young Women","volume":"338","author":"Ho","year":"1998","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3789","article-title":"HPV16 E2 is an Immediate Early Marker of Viral Infection, Preceding E7 Expression in Precursor Structures of Cervical Carcinoma","volume":"70","author":"Xue","year":"2010","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23490","article-title":"Effectiveness of HPV 16 Viral Load and the E2\/E6 Ratio for the Prediction of Cervical Cancer Risk Among Chinese Women","volume":"85","author":"Chang","year":"2013","journal-title":"J Med Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1874357901206010241","article-title":"The Immune Response to Papillomavirus During Infection Persistence and Regression","volume":"6","author":"Hibma","year":"2012","journal-title":"Open Virol J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2005.11.039","article-title":"Immunohistochemical Analysis of CD4+ and CD8+ T-Cell Subsets in High Risk Human Papillomavirus-Associated Pre-Malignant and Malignant Lesions of the Uterine Cervix","volume":"102","author":"Monnier-Benoit","year":"2006","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13027-018-0206-5","article-title":"Human Papilloma Virus E1-Specific T Cell Immune Response Is Associated With the Prognosis of Cervical Cancer Patients With Squamous Cell Carcinoma","volume":"13","author":"Ma","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24804","article-title":"A Prospective Study on the Natural Course of Low-Grade Squamous Intraepithelial Lesions and the Presence of HPV16 E2-, E6- and E7-Specific T-Cell Responses","volume":"126","author":"Woo","year":"2010","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12522","article-title":"Breadth of T Cell Responses After Immunization With Adenovirus Vectors Encoding Ancestral Antigens or Polyvalent Papillomavirus Antigens","volume":"85","author":"Ragonnaud","year":"2017","journal-title":"Scand J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82678-0","article-title":"Resolution of Cervical Dysplasia is Associated With T-Cell Proliferative Responses to Human Papillomavirus Type 16 E2","volume":"88","author":"Dillon","year":"2007","journal-title":"J Gen Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human Papillomavirus Type 16-Positive Cervical Cancer is Associated With Impaired CD4+ T-Cell Immunity Against Early Antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-015-0733-4","article-title":"Human Papillomavirus 16-Specific Cell-Mediated Immunity in Children Born to Mothers With Incident Cervical Intraepithelial Neoplasia (CIN) and to Those Constantly HPV Negative","volume":"13","author":"Koskimaa","year":"2015","journal-title":"J Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02093","article-title":"Non-Human Primate Papillomaviruses Share Similar Evolutionary Histories and Niche Adaptation as the Human Counterparts","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.07.012","article-title":"Genomic Diversity and Interspecies Host Infection of Alpha12 Macaca Fascicularis Papillomaviruses (Mfpvs)","volume":"393","author":"Chen","year":"2009","journal-title":"Virology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00233-07","article-title":"Characterization and Experimental Transmission of an Oncogenic Papillomavirus in Female Macaques","volume":"81","author":"Wood","year":"2007","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/CJI.0000000000000153","article-title":"Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix","volume":"40","author":"Ragonnaud","year":"2017","journal-title":"J Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.15.7616-7624.2002","article-title":"Ubiquitin-Fused and\/or Multiple Early Genes From Cottontail Rabbit Papillomavirus as DNA Vaccines","volume":"76","author":"Leachman","year":"2002","journal-title":"J Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/102.6.768","article-title":"Immunological Events in Regressing Genital Warts","volume":"102","author":"Coleman","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.3339","article-title":"MHC Class II-Associated Invariant Chain Linkage of Antigen Dramatically Improves Cell-Mediated Immunity Induced by Adenovirus Vaccines","volume":"180","author":"Holst","year":"2008","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.15","article-title":"Fusion of HCV Nonstructural Antigen to MHC Class II-Associated Invariant Chain Enhances T-Cell Responses Induced by Vectored Vaccines in Nonhuman Primates","volume":"22","author":"Capone","year":"2014","journal-title":"Mol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"eaaz7715","DOI":"10.1126\/scitranslmed.aaz7715","article-title":"MHC Class II Invariant Chain-Adjuvanted Viral Vectored Vaccines Enhances T Cell Responses in Humans","volume":"12","author":"Esposito","year":"2020","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11693-010-9062-3","article-title":"The Geneoptimizer Algorithm: Using a Sliding Window Approach to Cope With the Vast Sequence Space in Multiparameter DNA Sequence Optimization","volume":"4","author":"Raab","year":"2010","journal-title":"Syst Synth Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1038\/s41598-017-02460-2","article-title":"Systematic Comparison of 2A Peptides for Cloning Multi-Genes in a Polycistronic Vector","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01529-18","article-title":"Priming With a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses Prior to a Poxvirus and Protein Boost","volume":"93","author":"Asbach","year":"2019","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial","volume":"211","author":"Sarwar","year":"2015","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00149","article-title":"A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env Gp140 Protein\/Adjuvant HIV Vaccines in Two Immunization Regimes","volume":"8","author":"Joseph","year":"2017","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30262-0","article-title":"Safety and Immunogenicity of a Multivalent HIV Vaccine Comprising Envelope Protein With Either DNA or NYVAC Vectors (HVTN 096): A Phase 1b, Double-Blind, Placebo-Controlled Trial","volume":"6","author":"Pantaleo","year":"2019","journal-title":"Lancet HIV"},{"article-title":"Engineering Adenovirus Genome by Bacterial Artificial Chromosome (BAC) Technology BT - Adenovirus: Methods and Protocols","year":"2014","author":"Ruzsics","key":"B34"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.16.7297","article-title":"A Versatile Vector for Gene and Oligonucleotide Transfer Into Cells in Culture and In Vivo: Polyethylenimine","volume":"92","author":"Boussif","year":"1995","journal-title":"Proc Natl Acad Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41598-018-19874-1","article-title":"Vaccine Vectors Based on Adenovirus 19a\/64 Exhibit Broad Cellular Tropism and Potently Restimulate HCMV-Specific T Cell Responses Ex Vivo","volume":"8","author":"Kiener","year":"2018","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400197","article-title":"Priming of CD8 T Cells by Adenoviral Vectors is Critically Dependent on B7 and Dendritic Cells But Only Partially Dependent on CD28 Ligation on CD8 T Cells","volume":"193","author":"Nielsen","year":"2014","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e18556","DOI":"10.1371\/journal.pone.0018556","article-title":"High Cleavage Efficiency of a 2A Peptide Derived From Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice","volume":"6","author":"Kim","year":"2011","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.9.7297-7307.1999","article-title":"Multiple Functions of Human Papillomavirus Type 16 E6 Contribute to the Immortalization of Mammary Epithelial Cells","volume":"73","author":"Liu","year":"1999","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2012.55.A","article-title":"A non-Oncogenic HPV 16 E6\/E7 Vaccine Enhances Treatment of HPV Expressing Tumors","volume":"19","author":"Wieking","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.63.6.2650-2656.1989","article-title":"A Point Mutational Analysis of Human Papillomavirus Type 16 E7 Protein","volume":"63","author":"Edmonds","year":"1989","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.8828-8834.2005","article-title":"A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates","volume":"79","author":"Barouch","year":"2005","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801210","article-title":"Modified MHC Class II\u2013Associated Invariant Chain Induces Increased Antibody Responses Against Plasmodium Falciparum Antigens After Adenoviral Vaccination","volume":"202","author":"Fougeroux","year":"2019","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.22.11350-11358.2002","article-title":"Regulation of Bovine Papillomavirus Replicative Helicase E1 by the Ubiquitin-Proteasome Pathway","volume":"76","author":"Malcles","year":"2002","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.5.2615-2619.2004","article-title":"Bovine Papillomavirus Replicative Helicase E1 Is a Target of the Ubiquitin Ligase APC","volume":"78","author":"Mechali","year":"2004","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7150\/thno.21098","article-title":"Serum Immune Profiling for Early Detection of Cervical Disease","volume":"7","author":"Ewaisha","year":"2017","journal-title":"Theranostics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9450-2_9","article-title":"A SIINFEKL-Based System to Measure MHC Class I Antigen Presentation Efficiency and Kinetics","volume":"1988","author":"Dersh","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.002105-0","article-title":"Fusion of a Viral Antigen to Invariant Chain Leads to Augmented T-Cell Immunity and Improved Protection in Gene-Gun DNA-Vaccinated Mice","volume":"90","author":"Grujic","year":"2009","journal-title":"J Gen Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636233","article-title":"DNA Vaccine Encoding Endosome-Targeted Human Papillomavirus Type 16 E7 Protein Generates CD4+ T Cell-Dependent Protection","volume":"37","author":"Brulet","year":"2007","journal-title":"Eur J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.075","article-title":"Replication Deficient Human Adenovirus Vector Serotype 19a\/64: Immunogenicity in Mice and Female Cynomolgus Macaques","volume":"36","author":"Ragonnaud","year":"2018","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1001085","DOI":"10.1371\/journal.pgen.1001085","article-title":"Commercially Available Outbred Mice for Genome-Wide Association Studies","volume":"6","author":"Yalcin","year":"2010","journal-title":"PLoS Genet"},{"key":"B52","unstructured":"Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS\/LSIL2013"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e108892","DOI":"10.1371\/journal.pone.0108892","article-title":"Fusion of CTLA-4 With HPV16 E7 and E6 Enhanced the Potency of Therapeutic HPV DNA Vaccine","volume":"9","author":"Gan","year":"2014","journal-title":"PLoS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1487913","DOI":"10.1080\/2162402X.2018.1487913","article-title":"Potent Therapeutic Efficacy of an Alphavirus Replicon DNA Vaccine Expressing Human Papilloma Virus E6 and E7 Antigens","volume":"7","author":"van de Wall","year":"2018","journal-title":"Oncoimmunology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients With Cervical Intraepithelial Neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B56","unstructured":"This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers (Kingfisher)2018"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55014-z","article-title":"A Multi-Genotype Therapeutic Human Papillomavirus Vaccine Elicits Potent T Cell Responses to Conserved Regions of Early Proteins","volume":"9","author":"Hancock","year":"2019","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11010096","article-title":"HPV-16 E7 Antigen has Prophylactic and Therapeutic E Ffi Cacy in a Cervical Cancer Mouse Model","volume":"11","author":"Garza-Morales","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.4049\/jimmunol.1001251","article-title":"Vaccination Against Lymphocytic Choriomeningitis Virus Infection in MHC Class II-Deficient Mice","volume":"186","author":"Holst","year":"2011","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/immunohorizons.1900070","article-title":"Vaccinia Virus Vectors Targeting Peptides for MHC Class II Presentation to CD4(+) T Cells","volume":"4","author":"Hobbs","year":"2020","journal-title":"ImmunoHorizons"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.761214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:27:00Z","timestamp":1635406020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.761214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2021.761214"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.761214","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"article-number":"761214"}}